[HTML][HTML] Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis

C Reed, A Ibrahim, JE Edwards Jr, I Walot… - Antimicrobial agents …, 2006 - Am Soc Microbiol
C Reed, A Ibrahim, JE Edwards Jr, I Walot, B Spellberg
Antimicrobial agents and chemotherapy, 2006Am Soc Microbiol
Iron availability is a critical factor in the growth of Mucorales (5). Here we report the novel
use of deferasirox (Exjade; Novartis), an iron chelator recently approved by the US Food and
Drug Administration for the treatment of transfusionrelated iron overload (3), as salvage
therapy for a patient with progressive rhinocerebral mucormycosis. A 40-year-old man
presented to an outside hospital with diabetic ketoacidosis, left retrobulbar pain, and a left
cranial nerve VI palsy. The patient developed complete left ophthalmoplegia, blindness, and …
Iron availability is a critical factor in the growth of Mucorales (5). Here we report the novel use of deferasirox (Exjade; Novartis), an iron chelator recently approved by the US Food and Drug Administration for the treatment of transfusionrelated iron overload (3), as salvage therapy for a patient with progressive rhinocerebral mucormycosis.
A 40-year-old man presented to an outside hospital with diabetic ketoacidosis, left retrobulbar pain, and a left cranial nerve VI palsy. The patient developed complete left ophthalmoplegia, blindness, and worsening proptosis. He received amphotericin B lipid complex, but no surgery was performed. The patient was transferred to our institution on day 14 and
American Society for Microbiology